|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02616 CSTONE PHARMA-B
Nominal 
8.330 +1.430 (+20.725%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | -- | -- | 407,205 | 463,842 | 481,363 | 243,718 |
| Cost of Sales | -- | -- | (167,051) | (159,547) | (202,985) | (106,832) |
| Gross Profit | -- | -- | 240,154 | 304,295 | 278,378 | 136,886 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | -- | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | -- | -- | (91,207) | (367,234) | (902,678) | (1,920,100) | |
| Taxation | -- | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | -- | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (437,003) | 379.133% | (91,207) | (367,234) | (902,678) | (1,920,100) | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | -- | -- | 2,500 | (13,067) | (1,195) | (7,561) |
| Depreciation & Amortisation | -- | -- | 49,805 | 58,190 | 44,540 | 22,661 |
| Directors' Emoluments | -- | -- | 31,055 | 59,498 | 83,640 | 120,698 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -31.000 | 342.857% | -7.000 | -29.000 | -77.000 | -165.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.269) | (0.466) | (0.521) | (1.274) |
| NBV per share ($) | -- | -- | 0.283 | 0.356 | 0.375 | 1.017 |
| Remarks: | Real time quote last updated: 27/03/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -437,003 |
| %Change | 379.133% |
| EPS / (LPS) | RMB -0.310 |
| NBV Per Share (¥) | RMB -- |